One year ago to the day, ConcertAI and the American Society of Clinical Oncology (ASCO), the largest and most influential medical society in the world, entered into an agreement wherein the CancerLinQ program would become a ConcertAI initiative. As many of you know, CancerLinQ was formed by ASCO in 2013 as a technology-enabled quality initiative. Today, CancerLinQ represents one of the largest oncology real-world data and quality of care technology service entities in the world, uniquely bringing together clinical data from most major electronic medical record (EMR) systems. With a network of more than 100 cancer centers and oncology practices, 10 EMR system integrations, and data from nearly seven million patient records, CancerLinQ empowers oncology care teams and researchers with technology and data innovations to improve care and accelerate cancer research.
Since December of 2023, CancerLinQ has added new members and had exceptionally active engagement with heritage members. We have also initiated a wide range of investments, starting with the CARAai™ platform implementation, the next generation of the SmartLinQ SaaS solution layer, and foundation investments under formal agreement with ASCO, for ASCO Certified® the next generation of molecular treatment pathways and quality framework. In short, CancerLinQ is the largest learning healthcare network for clinical care and research in the world.
The future is exceptionally bright for CancerLinQ and its member institutions, with ever-increasing focus on automated quality and augmented clinical decision tools and next generation clinical research approaches. As we honor this one-year anniversary, the closing comments in our December 2023 announcement ring as clear today as then:
“The scope and scale of what CancerLinQ and ConcertAI can accomplish together is unprecedented,” said Eric P. Winer, MD, FASCO, Chair of the Board of ASCO. “We’ve successfully built a real-world data platform that delivers actionable insights to the cancer community – and now CancerLinQ is poised to sustain and increase its impact for oncology practices and patients for the long term.”
Best,
Jeff Elton & Louis Culot
